Findings

What do systematic reviews say?

88 questions · 88 findings · 11 reviews

No studies found 14 · 15.9%GRADE not reported 10 · 11.4%Very low 23 · 26.1%Low 8 · 9.1%Moderate 25 · 28.4%High 8 · 9.1%

Efficacy: remission (categorical) YMRS ≤ 12 and no increase in MADRS at end of study · acute mania

The review found no eligible studies for this question.

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acceptability: total withdrawals · acute mania

It is very uncertain whether lithium changes acceptability: total withdrawals compared with lamotrigine (very low certainty).

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
OR 0.8 [0.5, 1.29]
3 studies · 303 participants
Very low

Adverse event: tremor · acute mania

Lithium showed no clear difference in adverse event: tremor compared with lamotrigine (moderate certainty).

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
OR 1.28 [0.48, 3.41]
2 studies · 272 participants
Moderate

Somnolence · acute mania

Lithium showed no clear difference in adverse event: somnolence compared with lamotrigine (moderate certainty).

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
OR 1.14 [0.34, 3.85]
2 studies · 272 participants
Moderate

Seizure freedom · absence seizures in children and adolescents

1 finding from 1 review

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 365 participants
Moderate

80% or greater reduction in seizure frequency ‐ not reported · absence seizures in children and adolescents

It is very uncertain whether ethosuximide changes 80% or greater reduction in seizure frequency compared with valproate (very low certainty).

1 finding from 1 review

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents 2021 · Cochrane Headline outcomes only
RR 0.7 [0.19, 2.59]
1 study · 29 participants
Very low

50% or greater reduction in seizure frequency · absence seizures in children and adolescents

1 finding from 1 review

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 49 participants
Low

Normalisation of the EEG ‐ not reported · absence seizures in children and adolescents

The review found no eligible studies for this question.

1 finding from 1 review

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found